Phase 2
Completed N=39
Phase 2a Study of the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic Dermatitis
Source: ClinicalTrials.gov NCT04992546 ↗Enrolled (actual)
39
Serious AEs
0.0%
Results posted
Mar 2024
Primary outcomePrimary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 7; 12; 0; 0 Participants
Summary
This was a Ph2a study that consists of a double-blind, intra-patient placebo-controlled treatment period and an open-label uncontrolled treatment period with objective to evaluate the safety, tolerability, PK and preliminary efficacy of PRN473 in up to 40 patients with mild to moderate AD.
On Day 1 (Baseline) of the Blinded Period, 2 target lesions with a difference no greater than 1 point in Total Sign Score (TSS) were randomly assigned to treatment in an intra-patient 1:1 manner, one lesion to PRN473 and the other to matching placebo.
Participation took approximately 13 weeks, including up to a 5-week screening period, a 6-week treatment period, end of study assessments 1 day after last dose, and a safety follow-up phone call 2 weeks after last dose.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) |
7; 12; 0; 0 | — |
| PRIMARY Number of Participants With Potentially Clinically Significant Abnormalities (PCSA): Vital Signs |
0; 0; 0; 0 | — |
| PRIMARY Number of Participants With PCSA in 12-Lead Electrocardiogram (ECG) |
0; 1; 0; 0; 1; 0 | — |
| PRIMARY Number of Participants With PCSA: Hematology |
0; 1; 0; 0; 0; 0 | — |
| PRIMARY Number of Participants With PCSA: Electrolyte Parameters |
0; 0; 0; 0; 0; 0 | — |
| PRIMARY Number of Participants With PCSA: Metabolic Parameters |
0; 0; 2; 4; 0; 0 | — |
| PRIMARY Number of Participants With PCSA: Renal Function Parameters |
0; 0; 1; 3; 0; 0 | — |
| PRIMARY Number of Participants With PCSA: Liver Function Parameters |
0; 0; 0; 0; 0; 0 | — |
| PRIMARY Number of Participants With PCSA: Urinalysis |
0; 0; 0; 0; 0; 0 | — |
| PRIMARY Percentage of Participants With Application-Site Event During Double-Blind Period |
23.7; 17.9; 31.6; 25.6; 47.4; 48.7 | — |
| SECONDARY Maximum Plasma Concentration (Cmax) of SAR444727 |
0; 0; 0 | — |
Eligibility Criteria
Inclusion Criteria
- Male and female adults 18 to 70 years of age (inclusive) at the time of informed consent.
- Diagnosed with mild to moderate AD.
- History of AD for at least 6 months as determined by the Investigator through patient interview.
- Stable disease for the 4 weeks prior to the screening visit with no significant flares in AD as determined by the Investigator.
- Validated Investigator Global Assessment-atopic dermatitis (vIGA-AD) score of Moderate or Mild at Screening. The vIGA-AD was evaluated for the entire body except scalp, palms, soles and genitals.
- HadAD involvement (excluding scalp, palms, soles and genitals) of at least 1.0% BSA and no more than 14.0% BSA.
- Had at least two target lesions 100 cm2 or greater with a difference no greater than 1 point in lesion TSS and at least 5 cm apart located on the trunk (excluding genitals) or upper extremities (excluding palms).
- If female, patients with child-bearing potential must have a negative pregnancy test, and agree to practice true abstinence or agree to use highly effective contraception.
- If male, agree to use a male condom and highly effective contraception with female partners of child-bearing potential.
- In good health as judged by the Investigator.
Exclusion Criteria
- Patients who had failed 2 or more prior systemic treatments for AD.
- Patients who had received a live or attenuated vaccine in the last 12 weeks or intend to receive a live or attenuated vaccine during the study.
- Patients who cannot discontinue prohibited medications and treatments prior to the Baseline visit and during the study.
- Has unstable AD, based on the judgement of the Investigator, or any consistent requirement for high potency topical steroids to manage AD signs or symptoms.
- Patients who had significant active systemic or localized bacterial, viral, fungal, and helminth infection in the last 30 days.
- Patients unwilling to refrain from prolonged sun exposure or use of a tanning bed or other artificial light emitting devices for 4 weeks prior to Baseline and during the study.
- Patients with other skin conditions that would interfere with evaluations of the effect of the study medication on AD, as determined by the Investigator.
- Patients with known genetic dermatological conditions that overlap with AD, such as Netherton syndrome.
- Previous used of a BTK inhibitor.
- Women who were pregnant, wishing to become pregnant during the study, or were breastfeeding.
- Patients were undergoing allergy (eg, food allergy testing or skin prick testing), patch testing, or food challenges, or plan to do so during the study.
- Patients who had undergone major surgery within 4 weeks prior to Day 1 or patients who had a major surgery planned during the study.
- Regular use of drugs of abuse or regular alcohol consumption within 6 months prior to the study.
Data sourced from ClinicalTrials.gov (NCT04992546). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.